| Dr Mary Jo Logee, MD | |
|
3373 Commerce Pkwy, Suite 2, Wooster, OH 44691-7130 | |
| (330) 804-9712 | |
| (330) 804-9717 |
| Full Name | Dr Mary Jo Logee |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Sports Medicine |
| Location | 3373 Commerce Pkwy, Wooster, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184622912 | NPI | - | NPPES |
| 0891512 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083S0010X | Preventive Medicine - Sports Medicine | 35061022 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mary Jo Logee, MD 3373 Commerce Pkwy, Suite 2, Wooster, OH 44691-7130 Ph: (330) 804-9712 | Dr Mary Jo Logee, MD 3373 Commerce Pkwy, Suite 2, Wooster, OH 44691-7130 Ph: (330) 804-9712 |
News Archive
PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has opened two new Clinical Logistics Services facilities in emerging regions for biopharmaceutical development. PAREXEL's new depot in Singapore and ancillary warehouse in Russia will support its clients in more effectively managing their global clinical trial supply requirements.
Avid Radiopharmaceuticals, Inc. and PETNET Solutions, Inc., a wholly-owned subsidiary of Siemens Medical Solutions, USA, Inc., marked the first dose shipped from a PETNET Solutions manufacturing facility as part of its collaboration with Avid on Florbetapir F 18 (18F-AV-45 or Florbetapir), Avid's molecular imaging agent for positron emission tomography (PET) imaging of β-amyloid deposits in the brain, a key pathological component of Alzheimer's disease.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has completed the sale of $40 million of Series A Convertible Preferred Stock and warrants to purchase Series A Preferred to a group of institutional investors, including both existing and new investors, in a private placement.
Canadian researchers have discovered a previously hidden channel to attack leukemia and other cancer cells, according to a new study published in the Journal of Biological Chemistry. The findings from the Universit- de Montr-al, Maisonneuve-Rosemont Hospital and Universit- Laval may change the way doctors treat cancer patients.
Objet Ltd., the innovation leader in 3D printing for rapid prototyping and additive manufacturing today announced that Oratio B.V., a leading dental industry company in the Netherlands, has developed a complete in-house digital workflow for fabrication of models for dental implants with the help of an Objet 3D Printer.
› Verified 7 days ago